Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
05/08/20246:34AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:NINisource Inc
05/08/20246:34AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPSCOMPASS Pathways PLC
05/08/20246:33AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:DINOHF Sinclair Corporation
05/08/20246:33AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:WWWWolverine World Wide Inc
05/08/20246:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NXENexGen Energy Ltd
05/08/20246:33AMEdgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NYSE:BXSLBlackstone Secured Lending Fund
05/08/20246:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:HMDCFHUTCHMED China Ltd (PK)
05/08/20246:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HTHTH World Group Ltd
05/08/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:LLLL Flooring Holdings Inc
05/08/20246:30AMGlobeNewswire Inc.Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderTG:5Y6Compass Pathways Plc
05/08/20246:30AMGlobeNewswire Inc.Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical ProgramNASDAQ:VERUVeru Inc
05/08/20246:30AMGlobeNewswire Inc.Kraken Robotics Receives $3.5 Million of Orders for Subsea Security EquipmentTSXV:PNGKraken Robotics Inc
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
05/08/20246:30AMGlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
05/08/20246:30AMBusiness WireHF Sinclair Corporation Reports 2024 First Quarter Results and Announces Regular Cash DividendNYSE:DINOHF Sinclair Corporation
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaEU:MEDCLMedincell SA
05/08/20246:30AMBusiness WireEaton to supply innovative ELocker differential system to leading electrified vehicle manufacturer
05/08/20246:30AMGlobeNewswire Inc.Ducommun Incorporated Reports First Quarter 2024 ResultsNYSE:DCODucommun Inc
05/08/20246:30AMBusiness WireAult Alliance’s Subsidiary, Sentinum, Completes Initial Bitcoin Mining Installation at Montana LocationAMEX:AULTAult Alliance Inc
05/08/20246:30AMBusiness WireLubrizol Showcases LIPOFER™ Microencapsulation Technology, Introduces New EU Food-Grade Approval for Carbopol® Polymers at Vitafoods Europe 2024
05/08/20246:30AMGlobeNewswire Inc.Azimut and SOQUEM Cut Very High Grade Lithium Drill Intercepts on Galinée, James Bay Region, QuebecTSXV:AZMAzimut Exploration Inc
05/08/20246:30AMBusiness WireTeva et Medincell annoncent des résultats d'efficacité positifs pour l’essai de phase 3 SOLARIS de TEV-‘749 (olanzapine / mdc-TJK), injection sous-cutanée à action prolongée mensuelle pour les adultes atteints de schizophrénieEU:MEDCLMedincell SA
05/08/20246:30AMBusiness WireWolverine Worldwide Appoints Taryn Miller as Chief Financial OfficerNYSE:WWWWolverine World Wide Inc
05/08/20246:30AMBusiness WireTrane Technologies and the U.S. Department of Energy Partner to Advance Building Decarbonization in New Heat Pump Technology ChallengeNYSE:TTTrane Technologies plc
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaEU:MEDCLMedincell SA
05/08/20246:30AMBusiness WireAmerican Clinical Research Services Announces Strategic Acquisition of Elixia
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaEU:MEDCLMedincell SA
05/08/20246:30AMGlobeNewswire Inc.Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderNASDAQ:CMPSCOMPASS Pathways PLC
05/08/20246:30AMBusiness WireITT Announces Participation at 17th Annual Wolfe Research Global Transportation & Industrials Conference on May 22NYSE:ITTITT Inc
05/08/20246:30AMBusiness WireNiSource Announces First Quarter 2024 ResultsNYSE:NINisource Inc